CYDY - CytoDyn in discussions with regulators after CD12 data in COVID-19

CytoDyn (CYDY) announces that the CD12 COVID-19 trial data has been unblinded and the results will be reported when the Company has concluded its ongoing discussions with the regulatory agencies. CYDY expects to release CD12 data the complete results of its discussions with regulators in coming weeks.CytoDyn completed enrollment in late-stage trial in December 2020.In December 2020, the company secured FDA nod for protocol change in COVID-19 trial, which included adding an extension to its Phase 3 trial (CD12) for Vyrologix (leronlimab-PRO 140) in severe-to-critically ill COVID-19.

For further details see:

CytoDyn in discussions with regulators after CD12 data in COVID-19